Frontlight ResearchEarly access
Taking people in United StatesNo phase
Checking stomach movement problems in people with eosinophilic gastritis
Looks at whether eosinophilic gastritis affects how the stomach moves food, in adults.
Key facts
- Who runs it
- Children's Hospital Medical Center, Cincinnati
- Where
- Bethesda, Chicago, and Salt Lake City, United StatesSee the 3 sites
- Trial code
- Registry title
- Study of Gastric Motility in Eosinophilic Gastritis
- Status
- Recruiting
- People taking part
- 30 people, planned
- Started
- 25 Jan 2023
- Expected to end
- 1 Dec 2026
- Type of study
- Observational
- Record updated
- 31 March 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with eosinophilic gastritis (EG) who have symptoms that may point to slow stomach emptying. It studies whether EG affects how the stomach moves food.
- Age
- 18 Years to 59 Years
- Sex
- All sexes can join.
- Disease stage
- EG shown by at least one endoscopy (camera exam), with ≥ 30 eosinophils (a type of white blood cell) in 5 or more high powered fields. EG symptoms started at least one year before screening. Symptoms like nausea, vomiting, feeling full early or bloating after meals in the 60 days before screening.
- Earlier treatment
- People cannot have taken opioid medicines in the 2 weeks before screening or during the study. People cannot have had stomach surgeries or procedures such as pyloromyotomy, vagotomy, bariatric surgery or fundoplication.
- Biomarker or test result
- Tissue sample showing ≥ 30 eosinophils in 5 or more high powered fields.
Main reasons for not taking part
- Eosinophilic enteritis or inflammatory bowel disease (Crohn's disease, ulcerative colitis).
- Related disorders such as systemic mastocytosis, Marfan syndrome, systemic sclerosis, lupus or eosinophilic fasciitis.
- Uncontrolled diabetes or diabetes complications (gastroparesis, nerve or kidney damage).
- Narrowing of the stomach or small bowel, or past stomach surgery.
- Advanced liver disease (Child's B or C), kidney disease (serum creatinine > 3 mg/dL (265 µmol/L)), dysautonomia, achalasia or adrenal insufficiency.
The registry criteria, word for word
Show all 12 criteriaShow less
Who can take part
- Eosinophilic gastritis (EG) defined as at least one endoscopy with histopathologic evidence of ≥ 30 eosinophils in 5 or more high powered fields (hpf's) with associated symptoms of EG
- Patient reported symptoms starting at least one year or more prior to screening consistent with a diagnosis of EG: nausea, vomiting, early satiety, abdominal pain/bloating, regurgitation, diarrhea
- Symptoms suggestive of a possible gastric motility disorder during the 60 days prior to screening including: nausea, vomiting, early satiety, post-prandial feeling of fullness or bloating
- Tolerance and willingness to consume the oatmeal meal in this study
Who cannot take part
- Taking opioid agents in the 2 weeks prior to screening and throughout the study
- Inflammatory bowel disease (e.g., Crohn's disease or ulcerative colitis)
- Known disorders associated with eosinophilic gastrointestinal (GI) diseases (e.g., D 816 V Kit+ systemic mastocytosis, Marfan syndrome or Loey's Dietz Syndrome)
- Known inflammatory or autoimmune disorders associated with gastric dysmotility such as systemic sclerosis, lupus or eosinophilic fasciitis
- Uncontrolled diabetes or known diabetic complications of gastroparesis, neuropathy or nephropathy
- History of strictures in the small bowel or stomach (e.g., pyloric stenosis) or gastric surgeries or procedures such as pyloromyotomy, pyloric dilation, pyloric resection, vagotomy, bariatric surgery or post-Nissen fundoplication or antrectomy with Billroth I, Billroth II or Roux-en-Y gastrojejunostomy
- Past or current medical problems or findings such as: advanced liver disease (Child's B or C), acute or chronic renal disease (serum creatinine > 3 mg/dL), neurologic disease (e.g., dysautonomia), achalasia and adrenal insufficiency
- Diagnosis of eosinophilic enteritis
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 59 years old?
Where in United States
- The National Institutes of HealthBethesda, United StatesContact: Perla Adames-Castillo, RNTaking people
- Northwestern UniversityChicago, United StatesContact: Rose ArrietaTaking people
- University of UtahSalt Lake City, United StatesContact: Amy NicholsTaking people
About the trial
What the trial wants to find out
Purpose:
Read full original descriptionShow less
The study is a cross-sectional observational study designed to determine if eosinophilic gastritis (EG) results in gastric motility impairment.
Hypothesis:
Gastric dysfunction occurs in the natural history of EG but is underdiagnosed due, in part, to contraindications to the use of the standard meals used in gastric emptying studies.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Pilot Assessment to Find Evidence of Gastric Motility Abnormalities in Eosinophilic Gastric Disorders
- Plain-language title
- Checking stomach movement problems in people with eosinophilic gastritisGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 14 November 2026.
- Fit questions
- Built from NCT05229432, who can take part
- Record updated
- 31 March 2026